logo

Aeglea Biotherapeutics, Inc. (AGLE)



Trade AGLE now with
  Date
  Headline
8/5/2021 8:33:14 AM Aeglea BioTherapeutics Q2 Net Loss $6.8 Mln Vs. Net Loss $21.4 Mln Last Year
7/15/2021 8:39:59 AM Aeglea BioTherapeutics Appoints Jim Kastenmayer As General Counsel
7/8/2021 8:31:39 AM Aeglea BioTherapeutics Appoints Jonathan Alspaugh As CFO
6/24/2021 8:31:23 AM Aeglea BioTherapeutics Doses First Patient In Phase 1/2 Clinical Trial Of AGLE-177 For Homocystinuria
6/22/2021 8:32:21 AM Aeglea BioTherapeutics Appoints Marcio Souza To Board
5/3/2021 9:42:41 AM Aeglea Completes Patient Randomization For PEACE, Phase 3 Trial Of Pegzilarginase For Treatment Of Arginase 1 Deficiency
3/22/2021 8:46:40 AM Aeglea, Immedica In Commercialization Deal For Pegzilarginase For Treatment Of ARG1-D In Europe, Middle East
3/18/2021 8:38:30 AM Aeglea BioTherapeutics Q4 Net Loss $22.7 Mln Vs $21.5 Mln Last Year
12/17/2020 4:11:04 PM Aeglea BioTherapeutics Appoints Alison Lawton To Board Of Directors
12/1/2020 7:36:46 AM Aeglea BioTherapeutics Says FDA Granted Rare Pediatric Disease Designation To ACN00177 For Homocystinuria
12/1/2020 7:34:54 AM Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation For ACN00177 For Homocystinuria
11/5/2020 8:44:33 AM Aeglea BioTherapeutics Q3 Loss/shr $0.29 Vs. Loss/shr $0.66 Prior Year
10/26/2020 8:38:07 AM Aeglea BioTherapeutics Announces U.S., EU Orphan Drug Designations For ACN00177
4/28/2020 9:11:59 AM Aeglea BioTherapeutics Reports Pricing Of $120 Mln Public Offering
4/8/2020 7:38:17 AM Aeglea BioTherapeutics Announces Approval Of Clinical Trial Application By UK's MHRA For ACN00177